AR and prostate carcinoma: ARV-110 targeting androgen receptor (AR) and ARV-471 targeting estrogen receptor (ER), both of which are developed by Arvinas Inc. (New Haven, CT, USA) to combat prostate cancer and breast cancer, respectively, came into clinical trials in 2019 [132].